Care of the Cirrhotic Patient

Infectious Disease Clinics of North America

Volumn 26, Issue 4, 2012, Pages 979-994

  Jafri, Syed Mohammed ^a   Gordon, Stuart C ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Antimicrobial therapy; Cirrhosis; Hepatic decompensation; Viral hepatitis

Indexed keywords

BOCEPREVIR; CEFTRIAXONE; CIPROFLOXACIN; NORFLOXACIN; PEGINTERFERON; PLACEBO; RIBAVIRIN; RIFAXIMIN; TELAPREVIR; ANTIVIRUS AGENT;

ANEMIA; ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; CLINICAL FEATURE; DECOMPENSATED LIVER CIRRHOSIS; DRUG RESPONSE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; INFECTION PREVENTION; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NEUTROPENIA; PATIENT CARE; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VARICOSIS; VIROLOGY; VIRUS HEPATITIS;

ANTIVIRAL AGENTS; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION;

EID: 84867692171     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.08.009     Document Type: Review

References (130)

1. Heidelbaugh J.J., Bruderly M. Cirrhosis and chronic liver failure. Part I. Diagnosis and evaluation. Am Fam Physician 2006, 74:756-762.
2. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
3. Vigano M., Lampertico P., Rumi M.G., et al. Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients. Gastroenterology 2007, 133:835-842.
4. Freeman R.B., Wiesner R.H., Edwards E., et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004, 10:7-15.
5. Wiesner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124:91-96.
6. Shetty K., Rybicki L., Carey W.D. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 1997, 25:1049-1053.
7. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-648.
8. Malinchoc M., Kamath P.S., Gordon F.D., et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000, 31:864-871.
9. Kamath P.S., Kim W.R. The model for end-stage liver disease (MELD). Hepatology 2007, 45:797-805. Advanced Liver Disease Study Group.
10. Available at: Accessed April 6, 2012. http://www.mayoclinic.org/meld/mayomodel6.html.
11. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
12. Shah V.H., Kamath P.S. Portal hypertension and gastrointestinal bleeding. Sleisenger and Fordtran's gastrointestinal and liver disease 2006, 1899-1934. Saunders, Philadelphia. 8th edition. M. Feldman, L.S. Friedman, L.J. Brandt (Eds.).
13. Sherman K.E. Advanced liver disease: what every hepatitis C virus treater should know. Top Antivir Med 2011, 19(3):121-125.
14. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 112:463-472.
15. Serfaty L., Auma x12d;tre H., Chazouillères O., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998, 27:1435-1440.
16. Hu K.Q., Tong M.J. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999, 29:1311-1316.
17. Bhathal P.S., Grossman H.J. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985, 1:325-337.
18. Gupta T.K., Chung M.K., Toruner M., et al. Endothelial dysfunction in the intrahepatic microcirculation of the cirrhotic rat. Hepatology 1998, 28:926-931.
19. Ghany M.G., Strader D.B., Thomas D.L., et al. AASLD practice guidelines: diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
20. Machicao V.I., Fallon M.B. Hepatopulmonary syndrome. Semin Respir Crit Care Med 2012, 33(1):11-16.
21. Tafarel J.R., Tolentino L.H., Correa L.M., et al. Prediction of esophageal varices in hepatic cirrhosis by noninvasive markers. Eur J Gastroenterol Hepatol 2011, 23(9):754-758.
22. Pagliaro L., D'Amico G., Pasta L., et al. Portal hypertension in cirrhosis: natural history. Portal hypertension. pathophysiology and treatment 1994, 72-92. Blackwell Scientific, Oxford (United Kingdom). J. Bosch, R.J. Groszmann (Eds.).
23. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988, 319:983-989.
24. de Franchis R. Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005, 43:167-176.
25. Grace N.D., Groszmann R.J., Garcia-Tsao G., et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998, 28:868-880.
26. D'Amico G., Garcia-Tsao G., Cales P., et al. Diagnosis of portal hypertension: how and when. Portal hypertension III. Proceedings of the third baveno international consensus workshop on definitions, methodology and therapeutic strategies 2001, 36-64. Blackwell Science, Oxford (United Kingdom). R. de Franchis (Ed.).
27. Sempere L., Palazón J.M., Sánchez-Payá J., et al. Assessing the short- and long-term prognosis of patients with cirrhosis and acute variceal bleeding. Rev Esp Enferm Dig 2009, 101(4):236-248.
28. Boyer T.D., Haskal Z.J. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005, 41:386-400.
29. Abraldes J.G., Tarantino I., Turnes J., et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003, 37:902-908.
30. García-Pagán J.C., Caca K., Bureau C., et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010, 362:2370-2379. Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group.
31. Arroyo V., Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003, 38:S69-S89.
32. Runyon B.A. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med 1986, 146:2259-2261.
33. Bernardi M., Caraceni P., Navickis R.J. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012, 55:1172-1181.
34. Andreu M., Sola R., Sitges S.A., et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993, 104:1133-1138.
35. Gines A., Escorsell A., Gines P., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105:229-236.
36. Felisart J., Rimola A., Arroyo V., et al. Randomized comparative study of efficacy and nephrotoxicity of ampicillin plus tobramycin versus cefotaxime in cirrhotics with severe infections. Hepatology 1985, 5:457-462.
37. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.
38. Fernandez J., Acevedo J., Castro M. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012, 55:1551-1561.
39. Hoefs J.C., Canawati H.N., Sapico F.L., et al. Spontaneous bacterial peritonitis. Hepatology 1982, 2:399-407.
40. Runyon B.A. Ascites and spontaneous bacterial peritonitis. Sleisenger and Fortran's gastrointestinal and liver disease 2006, 1935-1964. Saunders, Philadelphia. 8th edition. M. Feldman, L.S. Friedman, L.J. Brandt (Eds.).
41. Garcia-Tsao G. Spontaneous bacterial peritonitis: a historical perspective. J Hepatol 2004, 41:522-527.
42. Ariza X., Castellote J., Lora-Tamayo J. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012, 56(4):825-832.
43. Rolachon A., Cordier L., Bacq Y., et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995, 22:1171-1174.
44. Runyon B.A., AASLD Practice Guidelines Committee Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009, 49:2087-2107.
45. Segarra-Newnham M., Henneman A. Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis in patients without gastrointestinal bleeding. Ann Pharmacother 2010, 44:1946-1954.
46. Terg R., Llano K., Cobas S., et al. Effect of oral ciprofloxacin on aerobic gram-negative flora of cirrhotic patients: results of short and long term administration with variable dose. Hepatology 1996, 24:455A.
47. Goel G.A., Deshpande A., Lopez R., et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012, 10:422-427.
48. Chavez-Tapia N.C., Barrientos-Gutierrez T., Tellez-Avila F., et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. An updated Cochrane review. Aliment Pharmacol Ther 2011, 34:509-518.
49. Soares-Weiser K., Brezis M., Tur-Kaspa R., et al. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev 2002, (2). CD002907.
50. Ngamruengphong S., Nugent K., Rakvit A., et al. Potential preventability of spontaneous bacterial peritonitis. Dig Dis Sci 2011, 56(9):2728-2734.
51. Fernández J., Ruiz del Arbol L., Gómez C., et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006, 131(4):1049-1056.
52. Christou L., Pappas G., Falagas M.E. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007, 102:1510-1517.
53. Rimola A., Soto R., Bory F., et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984, 4:53-58.
54. Akalin H.E., Laleli Y., Telatar H. Serum bactericidal and opsonic activities in patients with non-alcoholic cirrhosis. Q J Med 1985, 56:431-437.
55. Homann C., Varming K., Hogasen K., et al. Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997, 40:544-549.
56. Linderoth G., Jepsen P., Schonheyder H.C., et al. Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: a population-based cohort study. Alcohol Clin Exp Res 2006, 30:636-641.
57. Olson J.C., Wendon J.A., Kramer D.J., et al. Intensive care of the patient with cirrhosis. Hepatology 2011, 54:1864-1872.
58. Terra C., Guevara M., Torre A., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005, 129:1944-1953.
59. Caly W.R., Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993, 18:353-358.
60. Molle I., Thulstrup A.M., Svendsen N., et al. Risk and case fatality rate of meningitis in patients with liver cirrhosis. Scand J Infect Dis 2000, 32:407-410.
61. Pauwels A., Pines E., Abboura M., et al. Bacterial meningitis in cirrhosis: review of 16 cases. J Hepatol 1997, 27:830-834.
62. Campillo B., Richardet J.P., Kheo T., et al. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis 2002, 35:1-10.
63. Amdal T., Skinhoj P., Friis H. Bacteremia in patients suffering from cirrhosis. Infection 1986, 14:68-70.
64. Frenandez J., Navasa M., Gomez J., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002, 35:140-148.
65. Chen Y.M., Lee H.C., Chang C.M., et al. Clostridium bacteremia: emphasis on the poor prognosis in cirrhotic patients. J Microbiol Immunol Infect 2001, 34:113-118.
66. Arevalo M., Solera J., Cebrian D., et al. Risk factors associated with drug-resistant Mycobacterium tuberculosis in Castillala-Mancha. Eur Respir J 1996, 9:274-278.
67. Fede G., Spadaro L., Tomaselli T., et al. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology 2012, 55(4):1282-1291.
68. Fernández J., Escorsell A., Zabalza M., et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006, 44:1288-1295.
69. Sharma P., Singh S., Sharma B.C. Propofol sedation during endoscopy in patients with cirrhosis, and utility of psychometric tests and critical flicker frequency in assessment of recovery from sedation. Endoscopy 2011, 43(5):400-405.
70. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071-1081.
71. Cha C.H., Ruo L., Fong Y., et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 2003, 238:315-321.
72. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
73. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
74. Castells A., Bruix J., Bru C., et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993, 18:1121-1126.
75. Curley S.A., Izzo F., Ellis L.M., et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000, 232:381-391.
76. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
77. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
78. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
79. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
80. Sharma P., Balan V., Hernandez J.L., et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004, 10:36-41.
81. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
82. Cardoso A.C., Moucari R., Figueiredo-Mendes C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010, 52:652-657.
83. Simonetti J., Bulkow L., McMahon B.J., et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010, 51:1531-1537.
84. Bruix J, Sherman M, for the Practical Guidelines Committee. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Available at: Accessed April 16, 2012. https://www.aasld.org/practiceguidelines/Pages/default.aspx.
85. Shindo M., Hamada K., Oda Y., et al. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001, 33:1299-1302.
86. Yoshida H., Arakawa Y., Sata M., et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002, 123:483-491.
87. Bruno S., Stroffolini T., Colombo M., Italian Association of the Study of the Liver Disease (AISF), et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45:579-587.
88. Rincon D., Ripoll C., Lo Iacono O., et al. Antiviral therapy decreases hepaticvenous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006, 101:2269-2274.
89. Miyake Y., Takaki A., Iwasaki Y., et al. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010, 17:287-292.
90. Heathcote E.J., Shiffman M.L., Cooksley W.G., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673-1680.
91. Morrill J.A., Shrestha M., Grant R.W. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005, 20:754-758.
92. Butt A.A., Wagener M., Shakil A.O., et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005, 12:81-85.
93. Falck-Ytter Y., Kale H., Mullen K.D., et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288-292.
94. Shehab T.M., Orrego M., Chunduri R., et al. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003, 98:639-644.
95. Butt A.A., Justice A.C., Skanderson M., et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007, 56:385-389.
96. National Institutes of Health National Institutes of Health Consensus development conference statement: management of hepatitis C: June 10-12, 2002. Hepatology 2002, 36:S3-S20.
97. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:S237-S244.
98. Dienstag J.L., McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006, 130:231-264.
99. Clark B.T., Garcia-Tsao G., Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence 2012, 6:285-295.
100. Forns X., Bruix J. Treating hepatitis C in patients with cirrhosis: the effort is worth it. J Hepatol 2010, 52:624-626.
101. Somasundaram A., Venkataraman J. Antiviral treatment for cirrhosis due to hepatitis C: a review. Singapore Med J 2012, 53(4):231-235.
102. Carrion J.A., Martinez-Bauer E., Crespo G., et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009, 50:719-728.
103. Di Marco V., Almasio P.L., Ferraro D., et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007, 47:484-491.
104. Roffi L., Colloredo G., Pioltelli P., et al. Pegylated interferon alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008, 13:663-673. for the Gruppo Epatologico Lombardo.
105. Forns X., Garcia-Retortillo M., Serrano T., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003, 39:389-396.
106. Everson G.T., Trotter J., Forman L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255-262.
107. Roche B., Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int 2012, 32(Suppl 1):120-128.
108. Giannini E.G., Basso M., Savarino V., et al. Predictive value of ontreatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. J Intern Med 2009, 266:537-546.
109. Vezali E., Aghemo A., Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010, 32:2117-2138.
110. Iacobellis A., Siciliano M., Perri F., et al. Peginterferon alfa-2b and ribavirinin patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007, 46:206-212.
111. Ghany M.G., Nelson D.R., Strader D.B., American Association for Study of Liver Diseases, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
112. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838. PROVE1 Study Team.
113. Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850. PROVE2 Study Team.
114. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716. SPRINT-1 investigators.
115. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
116. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416. ADVANCE Study Team.
117. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011, 365:1014-1024. ILLUMINATE Study Team.
118. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
119. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
120. Hezode C., Dorival C., Zoulim F., et al. Telaprevir French cohort authorization for temporary use in genotype 1 hepatitis. J Hepatol 2012, 56:S4.
121. Collins B.H., Pirsch J.D., Becker Y.T., et al. Long-term results of liver transplantation in patients 60 years of age and older. Transplantation 2000, 70:780-783.
122. Berenguer M. Hepatitis C after liver transplantation: risk factors, outcomes, and treatment. Curr Opin Organ Transplant 2005, 10:81-89.
123. Samuel D., Forns X., Berenguer M., et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006, 45:127-143.
124. Available at: Accessed April 14, 2012. http://www.srtr.org/annual_reports/2010/914a_can-abo_li.htm.
125. Gane E.J., Portman B.C., Naoumov N.V., et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815-820.
126. Shuhart M.C., Bronner M.P., Gretch D.R., et al. Histological and clinical outcome after liver transplantation for hepatitis C. Hepatology 1997, 26:1646-1652.
127. Boker K.H., Dalley G., Bahr M., et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997, 25:203-210.
128. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002, 8:S14-S18.
129. Testa G., Crippin J.S., Netto G.J., et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000, 6:553-561.
130. Murray K.F., Carithers R.L. AASLD Practice Guidelines: evaluation of the patient for liver transplantation. Hepatology 2005, 41:1407-1432.